Targeting METTL3/m6A/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma
Combining SOCS3 restoration with anti-PD-1 therapy provides a preclinical proof-of-concept for potential combinatorial strategies to enhance immune responses in MM.